Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 4/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19553649 | 0.82 | PNMT (0.50) | PNMTTAAR1SLC6A2SLC6A3CSNK2A1 | |
| SCHEMBL12436727 | 0.80 | SIGMAR1 (0.58) | PNMTTAAR1SIGMAR1TMEM97KCNH2 | |
| Hydrochloric Acid SCHEMBL11679481 | 0.78 | BACE1 (0.51) | TAAR1SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL8847353 | 0.77 | PNMT (0.50) | PNMTTAAR1CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL25823578 | 0.77 | TMEM97 (0.44) | PNMTTAAR1SIGMAR1TMEM97KCNH2 | |
| SCHEMBL25823349 | 0.75 | TMEM97 (0.43) | PNMTTAAR1SIGMAR1TMEM97KCNH2 | |
| SCHEMBL27784805 | 0.74 | PNMT (0.44) | PNMTTAAR1SLC6A2SLC6A4SIGMAR1 | |
| SCHEMBL27881760 | 0.74 | PNMT (0.46) | PNMTTAAR1SIGMAR1CSNK2A1CSNK2A2 | |
| SCHEMBL28038231 | 0.73 | BACE1 (0.33) | — | |
| SCHEMBL28038236 | 0.73 | BACE1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | PNMT 1739/4885TAAR1 2235/4885SLC6A2 1438/4885 |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ADK, TNNI3K, TNK2 | PNMT 1739/4885TAAR1 2235/4885SLC6A2 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.